Anoxia Market research report- Global forecast till 2023

Anoxia Market Information: By Type (Anemic, Toxic, Stagnant, Anoxic), Diagnosis (MRI, CT Scan, EEG, Evoked Potential Test, Blood Test), Treatment (Cardiopulmonary Resuscitation, Rehabilitation Therapies, Medication), End User - Global Forecast till 2023

ID: MRFR/Pharma/3554-HCR | | Region: Global | 85 pages

Market Scenario


Anoxia is a condition that occurs due to complete loss of oxygen in body or brain which leads to various cognitive problems, and disabilities. It is considered as a severe cause of hypoxia. The most common causes of anoxia are respiratory arrest, drowning, carbon monoxide inhalation, illegal drug use, brain tumors, heart arrhythmia, suffocation, compression of the trachea, heart attack, and many others. Anoxic brain injury is also known as hypoxic-anoxic injury (HAI) or cerebral hypoxia. There are different types of anoxia, and each has an internal, and external causes. For instance, anemic anoxia occurs when blood is unable to carry enough oxygen to keep organs functioning properly, whereas, stagnant anoxia occurs when blood doesn’t reach brain or other body parts properly. Cardiovascular events such as, heart attack, cardiac arrhythmia, heart failure, and stroke, are the most common causes of stagnant anoxia. Anoxic anoxia usually at high altitudes. According to a study published in the Neural Regeneration Research journal, it is found that the with the increasing altitude partial pressure of oxygen falls which results in anoxic challenge to the person ascending to high altitudes.


Short-term memory loss, poor performance in executive functions, anomia, and visual disturbances are the commonly known cognitive problems associated with anoxia, whereas, physical problems include ataxia (lack of coordination), apraxia (inability to do common tasks), movement disorders, quadriparesis, and headaches.


Notably, rising cases of cardiac arrest is the key factor driving the anoxia market. According to a study published in the Critical Care journal in 2017, it is found that hypoxic ischemic brain injury (HIBI) is an outcome of cardiac arrest. It is stated that HIBI is the major cause of death in 23% of out-of-hospital cardiac arrest, and in 68% of inpatient cardiac arrest.


Various other factors such as, increasing awareness among people, increasing government assistance, and improvement in regulatory framework continuously contribute to the growth of the global anoxia market.


Despite these drivers, there are some issues associated with anoxia market. Challenges in research and development, and poor healthcare system in low and middle income countries may hinder the growth of market to an extent.


It is estimated that anoxia market is expected to grow at a CAGR 5.4% during the forecast period of 2017-2023.


Intended Audience



  • Pharmaceutical Companies

  • Research and Development (R&D) Companies

  • Diagnostic Laboratories

  • Government Research Institute

  • Academic Institutes and Universities


Segmentation


The anoxia market is segmented on the basis of type, diagnosis, treatment, and end-user.


On the basis of type, market is segmented into anemic anoxia, toxic anoxia, stagnant anoxia, and anoxic anoxia.


On the basis of diagnosis, market is classified into blood tests, MRI (magnetic resonance imaging), CT or CAT scan (computerized axial tomography), evoked potential tests, and EEG (electroencephalogram).


On the basis of treatment, market is classified into cardiopulmonary resuscitation (CPR), rehabilitation therapies, and medication. Rehabilitation therapies is further segmented into speech therapy physical therapy, occupational therapy, recreational therapy, and adaptive equipment training. Medication is also further classified into ammonia reducer, anticonvulsant, steroids, vitamin, and others.


On the basis of end-users, market is segmented into hospital & clinics, diagnostic centers, research institutes, rehabilitation Centers, and others.


Regional Analysis


The Americas dominate the anoxia market owing to the rise in awareness among people, and high healthcare expenditure. According to the Centers for Disease Control and Prevention, in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.


Europe holds the second position in anoxia market. It is expected that the support provided by government bodies for research & development and improvement in reimbursement policies in healthcare will drive the market in Europe region.


Asia Pacific is the fastest growing anoxia market owing to the huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare, in the years 2015 to 2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than expenditure of 2014–15.


The Middle East & Africa has the lowest market for anoxia due to lack of technical knowledge and poor medical facilities.


Key Players


Some of key the players in the anoxia market are Pfizer, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc,, Cephalon Inc., Shire, UCB S.A, and others.


Research Methodology
Anoxia Market


Sources: Annual reports, Press release, White paper, and Company presentation


 



Frequently Asked Questions (FAQ) :


anoxia market CAGR would be 5.4% during the forecast period.

anoxia market would get bogged down by lack of investment in research & development, and poor healthcare system in various low income countries.

anoxia market would be dominated by the Americas.

The players mentioned in the anoxia market Abbott Laboratories, Pfizer, GlaxoSmithKline plc, Novartis AG, Shire, UCB S.A, Cephalon Inc., and others.

The Asia Pacific anoxia market is the fastest-growing region.

Table of Contents:

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porter’s Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Anoxia Market, by Type

6.1 Introduction

6.2 Anemic Anoxia

6.2.1 Market Estimates & Forecast, 2016 – 2023

6.3 Toxic Anoxia

6.3.1 Market Estimates & Forecast, 2016 – 2023

6.4 Stagnant Anoxia

6.4.1 Market Estimates & Forecast, 2016 – 2023

6.5 Anoxic anoxia

6.5.1 Market Estimates & Forecast, 2016 – 2023

Chapter 7. Global Anoxia Market, by Diagnosis

7.1 Introduction

7.2 Blood Tests

7.2.1 Market Estimates & Forecast, 2017 – 2023

7.3 MRI (magnetic resonance imaging)

7.3.1 Market Estimates & Forecast, 2017 – 2023

7.4 CT or CAT scan (computerized axial tomography)

7.4.1 Market Estimates & Forecast, 2017 – 2023

7.5 Evoked Potential Tests

7.5.1 Market Estimates & Forecast, 2017 – 2023

7.6 EEG (electroencephalogram)

7.6.1 Market Estimates & Forecast, 2017 – 2023
Chapter 8. Global Anoxia Market, by treatment

8.1 Introduction

8.2 Cardiopulmonary Resuscitation (CPR)

8.2.1 Market Estimates & Forecast, 2018 – 2023

8.3 Rehabilitation Therapies

8.3.1 Market Estimates & Forecast, 2018 – 2023

8.4 Medication

8.4.1 Market Estimates & Forecast, 2018 – 2023

Chapter 9. Global Anoxia Market, by End User

9.1 Introduction

9.2 Hospital & Clinics

9.2.1 Market Estimates & Forecast, 2017 – 2023

9.3 Diagnostic Centers

9.3.1 Market Estimates & Forecast, 2017 – 2023

9.4 Research Institutes

9.4.1 Market Estimates & Forecast, 2017 – 2023

9.5 Rehabilitation Centers

9.5.1 Market Estimates & Forecast, 2017 – 2023

9.6 Others

Chapter 10. Global Anoxia Market, by Region

10.1 Introduction

10.2 Americas

10.2.1 North America

10.2.1.1 U.S.

10.2.1.1 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11 Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Pfizer

12.1.1 Company Overview

12.1.2 Types Overview

12.1.3 Financials

12.1.4 SWOT Analysis

12.2 Abbott Laboratories

12.2.1 Company Overview

12.2.2 Types Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Novartis AG

12.3.1 Company Overview

12.3.2 Types Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 GlaxoSmithKline plc

12.4.1 Company Overview

12.4.2 Types/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Cephalon Inc.

12.5.1 Company Overview

12.5.2 Types Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.6 Shire

12.6.1 Company Overview

12.6.2 Types Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.7 UCB S.A

12.7.1 Overview

12.7.2 Types Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Anoxia industry

Chapter 14 Appendix
LIST OF TABLES

Table 1 Anoxia Industry Synopsis, 2017 – 2023

Table 2 Anoxia Market Estimates and Forecast, 2017 – 2023, (USD Million)

Table 3 Anoxia Market by Region, 2017 – 2023, (USD Million)

Table 4 Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 5 Anoxia Market by Diagnosis, 2017 – 2023, (USD Million)

Table 6 Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 7 Anoxia Market by End Users, 2017 – 2023, (USD Million)

Table 8 North America Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 9 North America Anoxia Market by Diagnosis, 2017 – 2023, (USD Million)

Table 10 North America Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 11 North America Anoxia Market by End Users, 2017 – 2023, (USD Million)

Table 12 US Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 13 US Anoxia Market by Diagnosis, 2017 – 2023, (USD Million)

Table 14 US Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 15 US Anoxia Market by End Users, 2017 – 2023, (USD Million)

Table 16 Canada Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 17 Canada Anoxia market by Diagnosis, 2017 – 2023, (USD Million)

Table 18 Canada Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 19 Canada Anoxia market by End Users, 2017 – 2023, (USD Million)

Table 20 South America Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 21 South America Anoxia Market by Diagnosis, 2017 – 2023, (USD Million)

Table 22 South America Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 23 South America Anoxia Market by End Users, 2017 – 2023, (USD Million)

Table 24 Europe Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 25 Europe Anoxia Market by Diagnosis, 2017 – 2023, (USD Million)

Table 26 Europe Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 27 Europe Anoxia Market by End Users, 2017 – 2023, (USD Million)

Table 28 Western Europe Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 29 Western Europe Anoxia Market by Diagnosis, 2017 – 2023, (USD Million)

Table 30 Western Europe Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 31 Western Europe Anoxia Market by End Users, 2017 – 2023, (USD Million)

Table 32 Eastern Europe Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 33 Eastern Europe Anoxia market by Diagnosis, 2017 – 2023, (USD Million)

Table 34 Eastern Europe Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 35 Eastern Europe Anoxia Market by End Users, 2017 – 2023, (USD Million)

Table 36 Asia Pacific Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 37 Asia Pacific Anoxia Market by Diagnosis, 2017 – 2023, (USD Million)

Table 38 Asia Pacific Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 39 Asia Pacific Anoxia market by End Users, 2017 – 2023, (USD Million)

Table 40 Middle East & Africa Anoxia Market by Type, 2017 – 2023, (USD Million)

Table 41 Middle East & Africa Anoxia Market by Diagnosis, 2017 – 2023, (USD Million)

Table 42 Middle East & Africa Anoxia Market by Treatment, 2017 – 2023, (USD Million)

Table 43 Middle East & Africa Anoxia market by End Users, 2017 – 2023, (USD Million)


LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Anoxia Market

Figure 3 Segmentation Market Dynamics for Anoxia Market

Figure 4 Global Anoxia market Share, by Type 2016

Figure 5 Global Anoxia market Share, by Diagnosis 2016

Figure 6 Global Anoxia market Share, by Treatment 2016

Figure 7 Global Anoxia market Share, by End Users, 2016

Figure 8 Global Anoxia market Share, by Region, 2016

Figure 9 North America Anoxia market Share, by Country, 2016

Figure 10 Europe Anoxia market Share, by Country, 2016

Figure 11 Asia Pacific Anoxia market Share, by Country, 2016

Figure 12 Middle East & Africa Anoxia market Share, by Country, 2016

Figure 13 Global Anoxia market: Company Share Analysis, 2016 (%)

Figure 14 Pfizer: Key Financials

Figure 15 Pfizer Segmental Revenue

Figure 16 Pfizer: Geographical Revenue

Figure 17 Abbott Laboratories: Key Financials

Figure 18 Abbott Laboratories: Segmental Revenue

Figure 19 Abbott Laboratories: Geographical Revenue

Figure 20 Novartis AG: Key Financials

Figure 21 Novartis AG: Segmental Revenue

Figure 22 Novartis AG: Geographical Revenue

Figure 23 GlaxoSmithKline plc: Key Financials

Figure 24 GlaxoSmithKline plc: Segmental Revenue

Figure 25 GlaxoSmithKline plc: Geographical Revenue

Figure 26 Cephalon Inc.: Key Financials

Figure 27 Cephalon Inc.: Segmental Revenue

Figure 28 Cephalon Inc. Geographical Revenue

Figure 29 Shire: Key Financials

Figure 30 Shire: Segmental Revenue

Figure 31 Shire: Geographical Revenue

Figure 32 UCB S.A: Key Financials

Figure 33 UCB S.A: Segmental Revenue

Figure 34 UCB S.A: Geographical Revenue